Interpace Biosciences, Inc. (IDXG) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.24 means the share price is 0.24 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $36.1M is the value of all shares combined. Beta 0.61: the stock has moved about 39% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerInterpace Biosciences, Inc. (IDXG) trades at $6.51 with MoonshotScore 51/100 (Grade B). Interpace Biosciences, Inc. specializes in molecular diagnostic tests, bioinformatics, and pathology services, primarily focusing on evaluating cancer risk in the United States. Market cap: $36.1M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for IDXG: IDXG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IDXG against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
IDXG: 2/3 scored disciplines lean bullish. Dominant signal: Moon AI bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Interpace Biosciences, Inc. (IDXG) Healthcare & Pipeline Overview
Interpace Biosciences, Inc. is a U.S.-based healthcare company delivering specialized molecular diagnostic tests and bioinformatics services for cancer risk assessment. Leveraging platforms like PathFinderTG, it provides critical insights for pancreatic, thyroid, and lung cancer detection, positioning itself within the evolving precision medicine landscape.
What Is the Investment Thesis for IDXG?
The company's portfolio, including PancraGEN for pancreatic cancer and ThyGeNEXT/ThyraMIR for thyroid nodules, addresses critical diagnostic needs with proprietary technology. A notable financial highlight is its robust Profit Margin of 65.2% and Gross Margin of 62.5%, indicating strong operational efficiency relative to its revenue. With a P/E ratio of 0.24, the company demonstrates profitability. Growth catalysts include the increasing adoption of precision medicine, expansion of its diagnostic test offerings, and leveraging its bioinformatics capabilities for broader applications. The company's services to pharmaceutical and biotech industries also represent a stable revenue stream. However, its small market capitalization of $36.1M and OTC 'Other' tier classification introduce considerations regarding liquidity and disclosure, which potential investors must factor into their due diligence. The company's beta of 0.61 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
IDXG Key Highlights
Interpace Biosciences maintains a strong Profit Margin of 65.2%, indicating high profitability from its diagnostic services.
- The company demonstrates robust operational efficiency with a Gross Margin of 62.5%, showcasing effective cost management relative to its revenue.
- With a P/E ratio of 0.24, Interpace Biosciences is profitable, suggesting its earnings are substantial relative to its market valuation.
- The company's market capitalization stands at $36.1M, reflecting its status as a micro-cap entity within the diagnostics sector.
- Interpace Biosciences exhibits a Beta of 0.61, suggesting its stock price has historically been less volatile than the overall market.
Who Are IDXG's Competitors?
IDXG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MDXH MDxHealth SA | $0.68 | -2.31% | $34.7M | — |
| STRR Star Equity Holdings, Inc. | $10.45 | -0.48% | $38.6M | — |
| QUCY QUCY | $1.34 | -1.82% | $30.6M | — |
| BIOQ Bioqual, Inc. | $33.00 | 0.00% | $29.5M | 389-signal |
| PRPO Precipio, Inc. | $26.91 | +5.12% | $48.0M | — |
| DRIO DarioHealth Corp. | $6.90 | +4.86% | $50.5M | 335-pillar |
| SERA Sera Prognostics, Inc. | $2.05 | +1.99% | $78.3M | — |
| BNGO Bionano Genomics, Inc. | $1.22 | +1.67% | $14.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are IDXG's Key Strengths?
Proprietary and specialized molecular diagnostic tests for various cancers (pancreatic, thyroid, lung).
- Strong financial performance indicated by high Profit Margin (65.2%) and Gross Margin (62.5%).
- Diverse service offerings including pharmacogenomics and customized services for the biotech industry.
- Established customer base serving physicians, hospitals, and clinics across the U.S.
What Are IDXG's Weaknesses?
Small market capitalization ($36.1M) potentially limiting access to capital for large-scale expansion.
- Reliance on a relatively narrow range of specialized diagnostic tests.
- Operating on the OTC market, which can entail lower liquidity and less visibility.
- Disclosure status is 'Unknown' on the OTC market, potentially hindering investor confidence.
What Could Drive IDXG Stock Higher?
IDXG catalyst: Increased adoption rates for PancraGEN and ThyGeNEXT tests as awareness grows among healthcare providers regarding their diagnostic utility in cancer risk assessment.
- Expansion of services to pharmaceutical and biotech industries, including pharmacogenomics testing and biorepository services, driving diversified revenue streams.
- Potential for new product development or enhancements to existing diagnostic platforms, leading to broader market applications or improved diagnostic accuracy.
- Favorable shifts in healthcare reimbursement policies for molecular diagnostics, potentially improving access and financial viability for Interpace Biosciences' tests.
- Strategic partnerships or collaborations with larger healthcare organizations or research institutions to expand market reach and clinical validation efforts.
What Are the Key Risks for IDXG?
Financial-distress signal — its Altman Z-Score of -4.95 sits in the distress zone (elevated bankruptcy risk).
- Intense competition within the molecular diagnostics market from larger, well-funded companies could limit market share and pricing power for Interpace Biosciences.
- Regulatory changes or stricter oversight in the diagnostics industry could increase compliance costs and impact product development timelines.
- Dependence on a limited number of proprietary diagnostic tests means that any issues with these products, such as clinical efficacy or market acceptance, could significantly impact revenue.
- The 'Unknown' disclosure status on the OTC market poses a risk to investor confidence and makes it challenging to access timely, comprehensive financial information.
- Reimbursement challenges or unfavorable changes in insurance coverage for molecular diagnostic tests could reduce demand and profitability for the company's services.
What Are the Growth Opportunities for IDXG?
- **Expansion of Pancreatic Cancer Diagnostics Market Penetration:** The market for pancreatic cancer diagnostics is growing due to increasing incidence and the critical need for early detection. Interpace Biosciences' PancraGEN and PanDNA tests offer advanced genomic insights for pancreatic cyst and lesion risk assessment. Expanding sales and marketing efforts to a wider network of gastroenterologists, oncologists, and surgeons across the United States could significantly increase test volume. This opportunity leverages the existing proprietary PathFinderTG platform and addresses an unmet need for more precise risk stratification, potentially capturing a larger share of a market driven by an aging population and improved screening protocols over the next 3-5 years.
- **Increased Adoption of Thyroid Nodule Malignancy Assessment:** Thyroid cancer incidence has been rising, leading to a greater demand for accurate diagnostic tools for thyroid nodules. Interpace Biosciences' ThyGeNEXT and ThyraMIR tests provide complementary genomic and microRNA analyses to identify malignant nodules, reducing unnecessary surgeries. By demonstrating superior diagnostic accuracy and clinical utility through further studies and physician education, the company can drive broader adoption among endocrinologists and surgeons. This growth avenue capitalizes on a substantial patient population undergoing thyroid nodule evaluations, with potential for increased test utilization over the next 2-4 years as clinical guidelines evolve.
- **Leveraging Pharmacogenomics and Customized Services:** The pharmacogenomics market is expanding rapidly as personalized medicine gains traction, offering significant growth for companies providing related services. Interpace Biosciences already offers pharmacogenomics testing, genotyping, and biorepository services to pharmaceutical and biotech industries. By actively marketing these customized services, including contract research and development support, the company can attract new industry partners. This strategy diversifies revenue streams beyond direct patient diagnostics and taps into the robust R&D spending of the biopharmaceutical sector, with opportunities for long-term partnerships and recurring revenue over the next 5 years.
- **Development and Commercialization of New Diagnostic Solutions:** Continuous innovation in molecular diagnostics is crucial for sustained growth. Interpace Biosciences has a foundation in genomic and microRNA analysis, which can be extended to develop new diagnostic tests for other cancer types or disease areas. Investing in R&D to identify novel biomarkers and create new proprietary assays, potentially through collaborations with academic institutions or biotech firms, could open entirely new market segments. This forward-looking strategy positions the company for future market leadership and addresses evolving diagnostic needs, with new product launches potentially occurring within a 3-7 year timeframe.
- **Geographic Expansion and Strategic Partnerships:** While primarily serving the United States, there may be opportunities for Interpace Biosciences to explore strategic partnerships or licensing agreements to expand its diagnostic test offerings into international markets. The global demand for advanced cancer diagnostics is universal, and collaborating with established diagnostic providers in key regions could facilitate market entry without significant capital expenditure. Additionally, forming alliances with large healthcare systems or integrated delivery networks within the U.S. could streamline access to a broader patient base. This approach could unlock new revenue streams and enhance brand recognition over a 4-6 year horizon.
What Threats Does IDXG Face?
- Intense competition from larger, more diversified diagnostic companies with greater resources.
- Rapid technological advancements by competitors could render existing tests less competitive.
- Changes in healthcare reimbursement policies or regulatory landscape affecting diagnostic test coverage.
- Potential for adverse clinical study results or limited market acceptance of new diagnostic offerings.
What Are IDXG's Competitive Advantages?
- Proprietary diagnostic tests like PancraGEN, ThyGeNEXT, ThyraMIR, and RespriDx, which are based on unique genomic and microRNA assays.
- Specialized bioinformatics capabilities and the PathFinderTG platform, offering advanced analysis for complex diagnostic challenges.
- Clinical validation and established relationships with healthcare providers in niche cancer diagnostic areas.
- Expertise in pharmacogenomics and customized services, creating a specialized offering for the pharmaceutical and biotech industries.
- Regulatory approvals and intellectual property surrounding its diagnostic methodologies.
What Does IDXG Do?
Interpace Biosciences, Inc., incorporated in 1986 and headquartered in Parsippany, New Jersey, has evolved into a key provider of molecular diagnostic tests, bioinformatics, and pathology services dedicated to evaluating cancer risk across the United States. Initially known as Interpace Diagnostics Group, Inc., the company rebranded in November 2019 to better reflect its focus on advanced biosciences. Its core offerings include PancraGEN, a comprehensive genomic test for pancreatic cysts and pancreaticobiliary solid lesions, which utilizes the proprietary PathFinderTG platform to assist physicians in assessing cancer risk. Complementing this is PanDNA, a molecular-only version of PancraGEN providing a focused snapshot of limited factors. For thyroid cancer diagnostics, Interpace Biosciences offers ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules, and ThyraMIR, which assesses malignancy risk using a proprietary microRNA gene-expression assay. Additionally, RespriDx is a genomic test aiding physicians in differentiating metastatic or recurrent lung cancer. Beyond its direct diagnostic services, the company extends its expertise to the pharmaceutical and biotech industries, providing pharmacogenomics testing, genotyping, biorepository services, and various other customized solutions. Interpace Biosciences primarily serves a diverse client base comprising physicians, hospitals, and clinics, aiming to enhance diagnostic precision and patient care through its specialized molecular insights.
What Products and Services Does IDXG Offer?
- Provide molecular diagnostic tests for evaluating cancer risk, primarily in the United States.
- Offer PancraGEN, a genomic test for pancreatic cysts and pancreaticobiliary solid lesions using the PathFinderTG platform.
- Supply PanDNA, a molecular-only version of PancraGEN for focused risk assessment.
- Deliver ThyGeNEXT, an oncogenic mutation panel for identifying malignant thyroid nodules.
- Provide ThyraMIR, a microRNA gene-expression assay for assessing thyroid nodule malignancy risk.
- Offer RespriDx, a genomic test to differentiate metastatic or recurrent lung cancer.
- Conduct pharmacogenomics testing, genotyping, and biorepository services for pharmaceutical and biotech industries.
- Serve physicians, hospitals, and clinics with specialized diagnostic and pathology services.
How Does IDXG Make Money?
- Generate revenue through the sale and processing of proprietary molecular diagnostic tests to healthcare providers.
- Earn income by providing customized pharmacogenomics testing, genotyping, and biorepository services to pharmaceutical and biotech companies.
- Leverage proprietary platforms like PathFinderTG and specialized microRNA assays to offer unique diagnostic insights.
- Focus on high-value, specialized cancer diagnostics where precision and early detection are critical.
- Operate primarily on a fee-for-service model for diagnostic testing.
What Industry Does IDXG Operate In?
Interpace Biosciences operates within the Medical - Diagnostics & Research industry, a dynamic segment of the healthcare sector characterized by continuous innovation and increasing demand for precise, early disease detection. The broader market for molecular diagnostics is experiencing significant growth, driven by advancements in genomic sequencing, personalized medicine, and the rising global burden of chronic diseases, particularly cancer. Interpace Biosciences carves out a niche with its specialized molecular tests for pancreatic, thyroid, and lung cancers, areas where accurate and early diagnosis can significantly impact patient outcomes. The competitive landscape includes larger diagnostic companies and specialized biotech firms, all vying for market share through technological superiority, clinical validation, and market penetration. Interpace Biosciences' focus on proprietary genomic and microRNA assays positions it as a specialized player, aiming to differentiate through the efficacy and specificity of its diagnostic platforms like PathFinderTG.
Who Are IDXG's Key Customers?
- Physicians, including oncologists, gastroenterologists, endocrinologists, and pulmonologists.
- Hospitals and hospital systems seeking advanced diagnostic capabilities.
- Clinics and specialized medical practices.
- Pharmaceutical companies requiring pharmacogenomics and genotyping services.
- Biotechnology companies utilizing biorepository and customized research services.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 32 days ago
- ● No analyst coverage
Why 51?
This rating comes from our nine-signal model, which produces a score but not a per-factor breakdown. The sector-relative five-pillar model, which explains its own contributions, does not cover this listing yet. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 51 |
| 2026-08-26 | 51 |
| 2026-08-29 | 51 |
| 2026-09-01 | 51 |
| 2026-09-04 | 51 |
| 2026-09-07 | 51 |
| 2026-09-10 | 51 |
What changed?
The score has stayed at 51.
Over the same 18 days the stock moved +327.4%.
Company Profile
Interpace Biosciences, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Parsippany, US. The company is led by CEO Thomas W. Burnell. IDXG has traded publicly since 1998.
Interpace Biosciences, Inc. Financial Trajectory
Interpace Biosciences, Inc. (IDXG) reported $9.1M in revenue for Q2 FY2026, reflecting 1.1% growth compared to the prior quarter. The company recorded net income of $158K, with diluted EPS of $0.03. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, IDXG averaged $1.10 in diluted EPS.
How Interpace Biosciences, Inc. Is Valued
Interpace Biosciences, Inc. carries a market capitalization of $36.1M, placing it in the micro-cap category. Relative to its peer group, IDXG's quantitative score of 51/100 is above the peer average of 36/100.
Key Financial Metrics
Return on equity for Interpace Biosciences, Inc. stands at 215.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 70.8%, showing how much profit it generates from its asset base. IDXG trades at a trailing price-to-earnings ratio of 0.24, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 9.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.51 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 63.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Interpace Biosciences, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.95 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Interpace Biosciences, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 649.9% above estimates on average.
Insider Activity
Over the past six months, Interpace Biosciences, Inc. insiders filed 13 SEC Form 4 transactions — 3 sales and 10 purchases. On net that is roughly 3.0M shares acquired (about $742K) — insiders putting money in tends to read as conviction.
IDXG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary and specialized molecular diagnostic tests for various cancers (pancreatic, thyroid, lung).
- Strong financial performance indicated by high Profit Margin (65.2%) and Gross Margin (62.5%).
- Diverse service offerings including pharmacogenomics and customized services for the biotech industry.
- Established customer base serving physicians, hospitals, and clinics across the U.S.
Bear Case
- Small market capitalization ($36.1M) potentially limiting access to capital for large-scale expansion.
- Reliance on a relatively narrow range of specialized diagnostic tests.
- Operating on the OTC market, which can entail lower liquidity and less visibility.
- Disclosure status is 'Unknown' on the OTC market, potentially hindering investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $9M | $158,000 | $0.03 |
| Q1 FY2026 | $9M | $721,000 | $0.13 |
| Q4 FY2025 | $9M | $23M | $4.09 |
| Q3 FY2025 | $9M | $911,000 | $0.16 |
Q2 FY2026 · filed 10 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
IDXG Latest News
-
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
globenewswire.com · Aug 10, 2026
-
Stocks That Hit 52-Week Highs On Friday
· Feb 21, 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· Nov 26, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Nov 25, 2019
IDXG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IDXG.
Price Targets
Wall Street price target analysis for IDXG.
IDXG MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. IDXG scores 51/100 (Grade B): the number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed.
Latest News
Leadership: Thomas W. Burnell
CEO
Thomas W. Burnell serves as the CEO of Interpace Biosciences, Inc., leading a team of 111 employees. His career has been focused on guiding and developing companies within the healthcare and life sciences sectors. His experience is presumed to encompass operational management, strategic planning, and market development within the complex healthcare industry.
Track Record: Under Thomas W. Burnell's leadership, Interpace Biosciences has continued to focus on its core molecular diagnostic offerings, including PancraGEN, ThyGeNEXT, ThyraMIR, and RespriDx. His tenure has seen the company maintain strong gross and profit margins, reflecting efficient management of its specialized services. The company's rebranding in November 2019 from Interpace Diagnostics Group, Inc. to Interpace Biosciences, Inc. also occurred during a period of his leadership, signaling a strategic shift towards a broader biosciences identity.
IDXG OTC Market Information
Interpace Biosciences, Inc. trades on the OTC market under the 'OTC Other' tier. This classification generally applies to companies that do not meet the disclosure or financial standards for higher OTC tiers like OTCQX or OTCQB, or those that choose not to provide extensive public information. Unlike stocks listed on major exchanges such as NYSE or NASDAQ, which have stringent listing requirements for financial reporting, corporate governance, and minimum share prices, companies in the 'OTC Other' tier face fewer regulatory hurdles. This can result in less transparency and potentially higher risk for investors compared to exchange-listed securities.
- OTC Tier: OTC Other
- Limited public information and 'Unknown' disclosure status can hinder informed investment decisions and increase uncertainty.
- Lower liquidity on the 'OTC Other' market may result in wider bid-ask spreads and difficulty executing trades efficiently.
- Increased susceptibility to price manipulation and speculative trading due to less stringent regulatory oversight.
- Potential for delisting or further downgrading within the OTC tiers if disclosure or financial standards are not met.
- Difficulty in obtaining institutional investor interest due to the OTC listing and associated risks.
- Verify the latest available financial statements and reports, even if disclosure status is 'Unknown'.
- Research any news or press releases from the company or third-party sources for operational updates.
- Assess the company's competitive landscape and market position within the diagnostics industry.
- Evaluate the management team's experience and track record, especially in navigating OTC markets.
- Understand the specific risks associated with OTC 'Other' tier trading, including liquidity and transparency.
- Examine the company's product pipeline and intellectual property for long-term viability.
- Investigate any legal or regulatory actions against the company that might impact its operations.
- The company has a defined business in specialized molecular diagnostics for cancer risk assessment.
- It offers specific proprietary products like PancraGEN, ThyGeNEXT, ThyraMIR, and RespriDx.
- The company provides services to established pharmaceutical and biotech industries, indicating industry recognition.
- It has a physical headquarters in Parsippany, New Jersey, and a stated number of employees (111).
- The company was incorporated in 1986, suggesting a long operational history, albeit with a name change.
Common Questions About IDXG (Healthcare)
What does the AI Score mean for IDXG?
IDXG holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. The number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed.
Is IDXG a good stock?
Stock Expert AI does not rate IDXG buy, sell or hold. Interpace Biosciences, Inc. carries a MoonshotScore of 51/100 on the legacy nine-factor engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are Interpace Biosciences' primary diagnostic offerings and their applications?
Interpace Biosciences, Inc. specializes in a suite of molecular diagnostic tests for cancer risk assessment. Key offerings include PancraGEN, a genomic test for pancreatic cysts and lesions, which utilizes the PathFinderTG platform to assess cancer risk.
What are the key factors to evaluate for IDXG?
Interpace Biosciences, Inc. (IDXG) holds a MoonshotScore of 51/100 (moderate). P/E: 0.24x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does IDXG data refresh on this page?
IDXG's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IDXG's recent stock price performance?
Interpace Biosciences, Inc. (IDXG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary and specialized molecular diagnostic tests for various cancers (pancreatic, thyroid, lung). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IDXG overvalued or undervalued right now?
Interpace Biosciences, Inc. (IDXG) trades at 0.24x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of IDXG?
Yes, most major brokerages offer fractional shares of Interpace Biosciences, Inc. (IDXG) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track IDXG's earnings and financial reports?
Interpace Biosciences, Inc. (IDXG) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for IDXG earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO tenureYears could not be determined from the provided data.
- The 'Unknown' disclosure status for the OTC market was explicitly addressed in the relevant sections.